FSL-1, a bacterial-derived toll-like receptor 2/6 (TLR2/6) agonist, enhances resistance to experimental HSV-2 infection.
体外研究
FSL-1 significantly reduces HSV-2 replication in vitro. FSL-1 reduces HSV-2 replication in human vaginal epithelial cells (EC).
FSL-1 induces significant resistance to experimental genital HSV-2 infection through elaboration of a specific cytokine response profile.
FSL-1 enhances phagocytosis of bacteria by macrophages through a Toll-like receptor 2-mediated signalling pathway.
Cell Viability Assay
Cell Line:
V11I, V12I or V19I immortalized human vaginal EC
Concentration:
6 μg or 0.1 μg
Incubation Time:
Added at 24, 6 or just prior to HSV-2 inoculation (10pfu/well)
Result:
The 6 μg does produced significant reductions when delivered at 24 or 6 h prior to HSV-2 inoculation. The 0.1 μg dose produced reduced HSV-2 replication at 24 or 6 h prior to viral challenge.
分子式
C84H140N14O18S
分子量
1666.16
CAS号
322455-70-9
运输条件
Room temperature in continental US; may vary elsewhere.
储存方式
Please store the product under the recommended conditions in the Certificate of Analysis.